Nasus Pharma has announced the initiation of a Phase 1 PK study of its NS003 nasal powder ondansetron, which the company is developing for the treatment of nausea and vomiting following surgical procedures or chemotherapy. According to the company, a preclinical study demonstrated that NS003 had a similar PK profile compared to intravenous ondansetron. Nasus says that topline data from the Phase 1 trial are expected by the end of the year.
In addition to the ondansetron nasal powder, Nasus is developing a naloxone nasal spray and an epinephrine product based on its intranasal dry powder technology. Nasus recently announced that the FDA had cleared an IND for a pivotal study of NS002 epinephrine for the treatment of anaphylaxis, and initiation of that study is expected by the end of 2026.
Recently-hired Nasus Pharma CEO Brendan O’Grady commented, “Enrolling and dosing our first patient in this Phase 1 study of NS003 demonstrates our ability to execute on previous guidance, and we are very pleased to achieve this milestone. Ondansetron remains one of the most widely prescribed anti-emetics, with significant usage of the IV formulation in the hospital setting. A fast-onset, needle-free option could offer real value for patients who aren’t fully controlled on oral therapy. Intranasal administration of NS003 has the potential to address these unmet needs by offering a convenient, fast-onset alternative that may reduce avoidable clinic visits.”
Read the Nasus Pharma press release
